Gemzar approved for breast cancer

24 May 2004
News

Executive Summary

Lilly's Gemzar approved for use in combination with Bristol-Myers Squibb's Taxol for first-line treatment of metastatic breast cancer May 19. Clinical studies included in 1labeling show improvement in time to disease progression of 2.3 months over paclitaxel alone (5.2 versus 2.9 months). Overall response rate was 40.8% versus 22.1% for paclitaxel alone. Gemzar is already indicated for first-line non-small cell lung and pancreatic cancer...

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS044024

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS044024

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Gemzar approved for breast cancer

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert